(Q41138730)

27 September 2017

1 reference

title

The aminoglycosides (English)

1 reference

27 September 2017

R S Edson

1

1 reference

27 September 2017

C L Terrell

series ordinal

2

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 November 1991

1 reference

27 September 2017

1 reference

27 September 2017

volume

66

1 reference

27 September 2017

issue

11

1 reference

27 September 2017

page(s)

1158-1164

1 reference

Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Deafness Complicating Antibiotic Therapy of Hepatic Encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Pharmacology of Gentamicin in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Pharmacokinetics of Gentamicin in Children and Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Serum Protein Binding of the Aminoglycoside Antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

The pharmacokinetics of amikacin and gentamicin in volunteers: a comparison of individual differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Tobramycin and gentamicin concentrations in the serum of normal and anephric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Pharmacokinetics of amikacin in patients with impaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Autoradiographic Localization of [ 3 H]Gentamicin in the Proximal Renal Tubules of Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Penetration of Parenterally Administered Gentamicin into the Cerebrospinal Fluid in Experimental Meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Cerebrospinal fluid penetration of amikacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Gentamicin Levels in the Human Biliary Tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Gentamicin inactivation in purulent exudates: role of cell lysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Letter: Prolonged excretion of gentamicin in a patient with umimpaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Role of aminoglycoside antibiotics in the treatment of intra-abdominal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Five-year surveillance of aminoglycoside usage in a university hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Three-year experience with amikacin sulfate as an exclusive surgical aminoglycoside in a large acute-care hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Successful treatment of a pancreatic Nocardia asteroides abscess with amikacin and surgical drainage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Synergism of imipenem and amikacin in combination with other antibiotics against Nocardia asteroides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Antimicrobial susceptibility patterns of Nocardia asteroides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Prediction of creatinine clearance from serum creatinine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Identification of children for whom routine monitoring of aminoglycoside serum concentrations is not cost effective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

General mechanisms of resistance to antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Prevalence and mechanisms of aminoglycoside resistance. A ten-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Resistance to Six Aminoglycosidic Aminocyclitol Antibiotics Among Enterococci: Prevalence, Evolution, and Relationship to Synergism with Penicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Clinical nephrotoxicity of tobramycin and gentamicin. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Experimental studies on nephrotoxicity of aminoglycosides at low doses. Mechanisms and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

What is the cost of nephrotoxicity associated with aminoglycosides?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Once-daily aminoglycoside administration: new strategies for an old drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965798-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(12)65798-X

1 reference

27 September 2017

1 reference